Abstract
Purpose. This study is concerned with cellular delivery/generation of 2′-azido-2′-deoxyuridine and -deoxycytidine diphosphate (N3UDP or N3CDP), potent inhibitors of ribonucleotide reductase. It characterizes the phosphorylation steps involved in the conversion of 2′-azido-2′-deoxyuridine (N3Urd) and 2′-azido-2′-deoxycytidine (N3Cyd) to the corresponding diphosphates and explores a prodrug approach in cellular delivery of the inhibitor which circumvents the requirement of deoxynucleoside kinases.
Methods. Cell growth of CHO and 3T6 cells of known deoxycytidine kinase level was determined in the presence of N3Urd and N3Cyd. Activity of ribonucleotide reductase was determined in the presence of the azidonucleosides as well as their mono- or di-phosphates in a Tween 80-containing permeabilizing buffer. A prodrug of 5′-monophosphate of N3Urd was prepared and its biological activity was evaluated with CHO cells as well as with cells transfected with deoxycytidine kinase.
Results. N3Urd failed to inhibit the growth of both cell lines, while N3Cyd was active against 3T6 cells and moderately active against CHO cells. These results correlate with the deoxycytidine kinase levels found in the cells. Importance of the kinase was further established with the finding that the nucleoside analogs were inactive as reductase inhibitors in a permeabilized cell assay system while their mono- and di-phosphates were equally active. The prodrug was active in cell growth inhibition regardless of the deoxycytidine kinase level.
Conclusions. The azidonucleosides become potent inhibitors of the reductase by two sequential phosphorylation steps. The present study indicates that the first step to monophosphate is rate-limiting, justifying a prodrug approach with the monophosphate.
Similar content being viewed by others
REFERENCES
J. G. Cory. In J. G. Cory, A. H. Cory (eds.), Inhibitors of Ribonucleoside Diphosphate Reductase Activity; International encyclopedia of pharmacology and therapeutics, Pergamon Press, New York, 1989, pp 1–16.
Y. Engström, S. Eriksson, I. Jildevik, S. Skog, L. Thelander, and B. Tribukait. J. Biol. Chem. 260:9114–9116 (1985).
E. Lien. Prog. Drug Res. 31:101–126 (1987).
J. G. Cory, A. H. Cory, G. Rappa, A. Lorico, M.-C. Liu, T.-S. Lin, and A. C. Sartorelli. Biochem. Pharmacol. 48:335–344 (1994).
F. Lori, A. Malykh, A. Cara, D. Sun, J. N. Weinstein, J. Lisziewicz, and R. C. Gallo. Science. 266:801–805 (1994).
E. C. Moore and R. B. Hurlbert. Pharmac. Ther. 27:167–196 (1985).
G. Nocentini. Crit. Rev. Oncol. Hematol. 22:89–126 (1996).
S. P. Salowe, M. A. Ator, and J. Stubbe. Biochemistry. 26:3408–3416 (1987).
L. Åkerblom and P. Reichard. J. Biol. Chem. 260:9197–9202 (1985).
L. Thelander, B. Larsson, J. Hobbs, and F. Eckstein. J. Biol. Chem. 251:1398–1405 (1976).
J. P. Krise and V. J. Stella. Adv. Drug Delivery Rev. 19:287–310 (1996).
P. F. Torrence and B. Witkop. In L. Townsend, L. Tipson (eds.), Nucleic Acid Chemistry, Wiley, New York, 1978, pp 977–988.
D. M. Hapke, A. P. A. Stegmann, and B. S. Mitchell. Cancer Res. 56:2343–2347 (1996).
M. C. Alley, D. A. Scudiero, A. Monks, M. L. Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbott, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd. Cancer Res. 48:589–601 (1988).
N. S. Datta, D. S. Shewach, M. C. Hurley, B. S. Mitchell, and I. H. Fox. Biochemistry, 28:114–123 (1989).
J. A. Wright, R. G. Hards, and J. E. Dick. Adv. Enz. Reg. 19:105–127 (1981).
J. Balzarini. Pharm. World & Sci. 16:113–126 (1994).
F. M. Sirotnak and J. R. Barrueco. Cancer Metast. Rev. 6:459–480 (1987).
J.-P. Sommadossi. Clin. Inf. Dis. 16:S7–S15 (1993).
B. E. Griffin and A. Todd. J. Chem. Soc. 1389–1393 (1958).
G. M. T. van Wijk, K. Y. Hostetler, and H. van den Bosch. Biochim. Biophys. Acta. 1084:307–310 (1991).
J. Sarup and A. Fridland. Biochemistry, 26:590–597 (1987).
E. S. J. Arnér and J. Eriksson. Pharmac. Ther. 67:155–186 (1995).
E. P. Anderson. In P. D. Boyer (Ed) The Enzymes, Academic Press, New York, 1973, pp. 49–96.
D. Farquhar, S. Khan, D. N. Srivastva, and P. P. Saunders. J. Med. Chem. 37:3902–3909 (1994).
R. Tsien and T. Pozzan. Methods Enzymol. 172, 230–262 (1989).
C. Schultz, M. Vajanaphanich, A. T. Harootunian, P. J. Sammak, K. E. Barrett, and R. Y. Tsien. J. Biol. Chem. 268:6316–6322 (1993).
D. Roberts. Biochemistry 5:3546–3548 (1966).
U. R. Kees, J. Ford, V. M. Dawson, E. Piall, and G. W. Aherne. Cancer Res. 49:3015–3019 (1989).
D. H. W. Ho. Biochem. Pharmacol. 20:3538–3539 (1971).
J.-J. Vasseur, D. Peoc'h, B Rayner, and J.-L. Imbach. Nucleosides Nucleotides 10:107–117 (1991).
F. Sinigaglia and K. W. Talmadge. Eur. J. Immunol. 15:692–696 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kang, S.H., Sinhababu, A.K., Cory, J.G. et al. Cellular Delivery of Nucleoside Diphosphates: A Prodrug Approach. Pharm Res 14, 706–712 (1997). https://doi.org/10.1023/A:1012133902314
Issue Date:
DOI: https://doi.org/10.1023/A:1012133902314